Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
OTHER OTC:OPT
See the Price Targets and Ratings of:
OPT Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$12→$1
Hold
400.00%
Upside
Downgraded
03/26/25
Jefferies
$1
Sell
400.00%
Upside
Downgraded
03/25/25
Oppenheimer
―
Hold
―
Downgraded
03/24/25
JonesTrading
$13
Buy
6400.00%
Upside
Reiterated
03/03/25
Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 TargetWe have incorporated Opthea’s latest financial results in our model. We have adjusted our expense estimates as well as non-cash interest projections based on the trajectory. Our DCF based PT remains at $13. Upcoming Catalysts. (1) Topline data from Phase 3 trials, COAST (sozinibercept + aflibercept) and ShORe (sozinibercept + ranibizumab) in wAMD in early 2Q25 and mid-25, respectively; (2) potential BLA filing for sozinibercept in wAMD in 1H 2026; and (3) Potential US launch in 2027 (Jones estimate) Symbol OPT Price (Feb 28, 2025) $4.48 Market Cap (MM) $994 Dividend NA Enterprise Value (MM) $821 Shares/Units Outstanding (MM) 187.7 Dividend Yield NA Free Float (MM) NA Free Float % NA 52-Week Range $1.79—$6.30 3-Month Avg. Daily Vol. 24,944 Short Interest (% of Float) NA Total Assets (MM) $144 Cash & Cash Eq.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$12→$1
Hold
400.00%
Upside
Downgraded
03/26/25
Jefferies
$1
Sell
400.00%
Upside
Downgraded
03/25/25
Oppenheimer
―
Hold
―
Downgraded
03/24/25
JonesTrading
$13
Buy
6400.00%
Upside
Reiterated
03/03/25
Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 TargetWe have incorporated Opthea’s latest financial results in our model. We have adjusted our expense estimates as well as non-cash interest projections based on the trajectory. Our DCF based PT remains at $13. Upcoming Catalysts. (1) Topline data from Phase 3 trials, COAST (sozinibercept + aflibercept) and ShORe (sozinibercept + ranibizumab) in wAMD in early 2Q25 and mid-25, respectively; (2) potential BLA filing for sozinibercept in wAMD in 1H 2026; and (3) Potential US launch in 2027 (Jones estimate) Symbol OPT Price (Feb 28, 2025) $4.48 Market Cap (MM) $994 Dividend NA Enterprise Value (MM) $821 Shares/Units Outstanding (MM) 187.7 Dividend Yield NA Free Float (MM) NA Free Float % NA 52-Week Range $1.79—$6.30 3-Month Avg. Daily Vol. 24,944 Short Interest (% of Float) NA Total Assets (MM) $144 Cash & Cash Eq.
Best Analysts Covering Opthea Limited Sponsored ADR
1 Month
xxx
Success Rate
2/4 ratings generated profit
Average Return
+8.48%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +8.48% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
Average Return
-15.07%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -15.07% per trade.
1 Year
Success Rate
1/4 ratings generated profit
Average Return
-70.58%
reiterated a buy rating 10 months ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -70.58% per trade.
2 Years
xxx
Success Rate
0/4 ratings generated profit
Average Return
-96.15%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -96.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OPT Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
Aug 25
Strong Buy
3
5
6
3
1
Buy
1
1
1
0
0
Hold
4
4
8
4
5
Sell
4
3
4
3
3
Strong Sell
0
0
1
1
1
total
12
13
20
11
10
Each month's total comprises the sum of three months' worth of ratings.
OPT Stock Forecast FAQ
What is OPT’s average 12-month price target, according to analysts?
Currently, no data Available
What is OPT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for OPT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OPT a Buy, Sell or Hold?
Opthea Limited Sponsored ADR has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Opthea Limited Sponsored ADR’s price target?
Currently, no data Available
What do analysts say about Opthea Limited Sponsored ADR?
Opthea Limited Sponsored ADR’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of OPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.